|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
The RNAi therapeutics roller coaster
If you have a question about this talk, please contact Thomas Irving.
Part of the Biotechnology lecture series
The discovery of RNAi interference gene suppression in humans opened up the prospect of creating a transformative new class of medicines similar in importance to small molecules and monoclonal antibodies. A decade on, amid steady scientific progress, RNAi therapeutics has gone from most-hyped to most-ridiculed technology before entering the current phase in which, for the first time, business expectations and scientific realities have begun to align.
In his talk, Dr Haussecker will be discussing the factors that have been driving the rapid swings in public/investor perceptions and will try to distill general lessons applicable to the development of other new biotechnology platforms. Although the jury is still out, the evidence, including well-received recent clinical trial results, point towards developing solutions to technical bottlenecks and building scientific credibility to be the most rewarding early-stage business development strategy.
Date: Wednesday 21st November Time: 7PM Location: Plant Sciences lecture theatre, Downing Site. [map: www.map.cam.ac.uk] Free for BioSoc members; 1 pound entry for non-members.
This talk is part of the Cambridge University Biological Society series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsThe Cambridge University City Seminar at CRASSH Assessment Practice Graduate Workshops in Economic and Social History
Other talksOrigin of coherence dynamics in biological complexes Autophagy signalling regulation and cancer: don't mess with the cell cycle Members' talks/slides/presentations No Talk: Summer conference "Mind the Gap" Reprogramming Immune Microenvironments in Solid Tumors to Enhance Therapy CCE Seminar - Caribbean Poetry Project (title to be confirmed)